NASDAQ:HOWL Werewolf Therapeutics (HOWL) Stock Price, News & Analysis → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free HOWL Stock Alerts $4.46 -0.59 (-11.68%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$4.40▼$5.1750-Day Range$4.69▼$7.0352-Week Range$1.57▼$8.19Volume353,815 shsAverage Volume229,640 shsMarket Capitalization$193.83 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Werewolf Therapeutics alerts: Email Address Werewolf Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside162.0% Upside$12.00 Price TargetShort InterestHealthy1.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.52) to ($1.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.31 out of 5 starsMedical Sector494th out of 925 stocksPharmaceutical Preparations Industry229th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingWerewolf Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageWerewolf Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Werewolf Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.39% of the float of Werewolf Therapeutics has been sold short.Short Interest Ratio / Days to CoverWerewolf Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Werewolf Therapeutics has recently increased by 1.07%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldWerewolf Therapeutics does not currently pay a dividend.Dividend GrowthWerewolf Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HOWL. Previous Next 1.8 News and Social Media Coverage News SentimentWerewolf Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Werewolf Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for HOWL on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Werewolf Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Werewolf Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.10% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.84% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Werewolf Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.52) to ($1.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Werewolf Therapeutics is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Werewolf Therapeutics is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWerewolf Therapeutics has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Werewolf Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceHave you heard of the $11 AI Coin?A new set of AI startups are rising... Except you won't find them on the stock market.Find out more about this $11 AI Coin right now About Werewolf Therapeutics Stock (NASDAQ:HOWL)Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.Read More HOWL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HOWL Stock News HeadlinesMay 9, 2024 | americanbankingnews.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) to Post Q2 2024 Earnings of ($0.40) Per Share, HC Wainwright ForecastsMay 8, 2024 | markets.businessinsider.comWerewolf Therapeutics: Buy Rating Affirmed Amid Promising Clinical Advancements and Pipeline PotentialMay 13, 2024 | InvestorPlace (Ad)Elon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.May 8, 2024 | americanbankingnews.comWerewolf Therapeutics (NASDAQ:HOWL) Stock Rating Reaffirmed by JMP SecuritiesMay 8, 2024 | americanbankingnews.comWedbush Reiterates Outperform Rating for Werewolf Therapeutics (NASDAQ:HOWL)May 8, 2024 | americanbankingnews.comWerewolf Therapeutics (NASDAQ:HOWL) Stock Rating Reaffirmed by HC WainwrightMay 6, 2024 | markets.businessinsider.comThe Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 ExpertsMay 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Werewolf Therapeutics Amid Promising Financials and Anticipated Clinical UpdatesMay 13, 2024 | InvestorPlace (Ad)Elon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.May 3, 2024 | investorplace.comHOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Misses Revenue for Q1 2024May 3, 2024 | yahoo.comHowl: Leonardo DiCaprio Working on Live-Action Movie Told From a Dog and Wolf’s PerspectiveMay 3, 2024 | globenewswire.comWerewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 2, 2024 | yahoo.comMy patient thinks he’s a werewolf: 10 years as an NHS psychiatristMay 1, 2024 | msn.comHowling Deal: Great Wolf Lodge offers $84 specialApril 30, 2024 | msn.comWhy Do Dogs Howl? 6 Top Reasons Your Dog HowlsApril 24, 2024 | globenewswire.comWerewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2024 | finance.yahoo.comWerewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual MeetingApril 23, 2024 | globenewswire.comWerewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual MeetingApril 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Werewolf Therapeutics on Promising PREDATOR Platform Prospects and Strong Pipeline PotentialApril 12, 2024 | msn.comWhy Howl's turn-based tactics are ideal for mobileApril 5, 2024 | globenewswire.comWerewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual MeetingApril 4, 2024 | seekingalpha.comWerewolf Therapeutics: In The Hunt For Success In The Cytokine SpaceApril 4, 2024 | globenewswire.comWerewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual MeetingMarch 15, 2024 | morningstar.comWerewolf Therapeutics Inc HOWLMarch 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Werewolf Therapeutics with Anticipated Surge on WTX-124 Phase 1 Data ReleaseMarch 9, 2024 | finance.yahoo.comWerewolf Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 7, 2024 | markets.businessinsider.comBuy Rating Reiterated for Werewolf Therapeutics Amid Promising INDUKINE Platform DevelopmentsSee More Headlines Receive HOWL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/13/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HOWL CUSIPN/A CIK1785530 Webwerewolftx.com Phone617-952-0555FaxN/AEmployees47Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+144.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,370,000.00 Net Margins-256.33% Pretax Margin-256.33% Return on Equity-36.15% Return on Assets-23.29% Debt Debt-to-Equity Ratio0.24 Current Ratio6.71 Quick Ratio6.71 Sales & Book Value Annual Sales$19.94 million Price / Sales10.70 Cash FlowN/A Price / Cash FlowN/A Book Value$3.08 per share Price / Book1.59Miscellaneous Outstanding Shares43,460,000Free Float34,286,000Market Cap$213.39 million OptionableOptionable Beta0.71 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Daniel J. Hicklin Ph.D. (Age 60)Founder, CEO, President, Secretary & Director Comp: $928.26kKey CompetitorsAldeyra TherapeuticsNASDAQ:ALDX2seventy bioNASDAQ:TSVT23andMeNASDAQ:MEFoghorn TherapeuticsNASDAQ:FHTXImmutepNASDAQ:IMMPView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 233,909 shares on 5/10/2024Ownership: 2.554%Acadian Asset Management LLCBought 94,212 shares on 5/10/2024Ownership: 0.399%HBK Sorce Advisory LLCSold 13,227 shares on 5/9/2024Ownership: 0.031%Denali Advisors LLCBought 26,600 shares on 4/19/2024Ownership: 0.061%PFM Health Sciences LPBought 909,895 shares on 2/15/2024Ownership: 8.529%View All Institutional Transactions HOWL Stock Analysis - Frequently Asked Questions Should I buy or sell Werewolf Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HOWL shares. View HOWL analyst ratings or view top-rated stocks. What is Werewolf Therapeutics' stock price target for 2024? 3 brokerages have issued 1-year price targets for Werewolf Therapeutics' stock. Their HOWL share price targets range from $9.00 to $15.00. On average, they anticipate the company's share price to reach $12.00 in the next year. This suggests a possible upside of 162.0% from the stock's current price. View analysts price targets for HOWL or view top-rated stocks among Wall Street analysts. How have HOWL shares performed in 2024? Werewolf Therapeutics' stock was trading at $3.86 at the start of the year. Since then, HOWL shares have increased by 18.7% and is now trading at $4.58. View the best growth stocks for 2024 here. When is Werewolf Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our HOWL earnings forecast. How were Werewolf Therapeutics' earnings last quarter? Werewolf Therapeutics, Inc. (NASDAQ:HOWL) issued its quarterly earnings results on Thursday, March, 7th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.10. The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $2.75 million. Werewolf Therapeutics had a negative net margin of 256.33% and a negative trailing twelve-month return on equity of 36.15%. When did Werewolf Therapeutics IPO? Werewolf Therapeutics (HOWL) raised $101 million in an initial public offering (IPO) on Friday, April 30th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. Who are Werewolf Therapeutics' major shareholders? Werewolf Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.55%), Acadian Asset Management LLC (0.40%), Denali Advisors LLC (0.06%) and HBK Sorce Advisory LLC (0.03%). Insiders that own company stock include Ra Capital Management, LP and Reid Leonard. View institutional ownership trends. How do I buy shares of Werewolf Therapeutics? Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HOWL) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorBill Clinton Backing Biden Replacement???The Freeport SocietyThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
